Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Phase I Clinical Trial to Assess the Safety of Whole Blood Treated With Amustaline (S-303) and Glutathione (GSH), a Pathogen Reduction System, in Anemic Patients

NCT04020224 is registered in ClinicalTrials.gov with Swiss Transfusion SRC as lead sponsor.

NCT NCT04020224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04020224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Phase I Clinical Trial to Assess the Safety of Whole Blood Treated With Amustaline (S-303) and Glutathione (GSH), a Pathogen Reduction System, in Anemic Patients
Lead sponsor
Swiss Transfusion SRC
Phase
Not applicable
Overall status
Withdrawn
Start date
January 31, 2024
Completion date
March 31, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

safety issues